ΔPK oncolytic activity includes modulation of the tumour cell milieu

Area of Science:

• Oncolytic virotherapy
• Cancer immunology
• Tumor microenvironment

Background:

• Oncolytic virotherapy shows modest clinical efficacy due to immunosuppressive tumor microenvironments.
• Herpes simplex virus type 2 (HSV-2)-based oncolytic virus ΔPK demonstrates anti-tumor activity.
• The mechanism by which ΔPK reverses tumor immunosuppression requires further investigation.

Purpose of the Study:

• To investigate if ΔPK-mediated oncolysis can reverse the immunosuppressive tumor microenvironment in melanoma.
• To elucidate the mechanisms underlying ΔPK's immunomodulatory effects.
• To determine the role of cytokine balance and immune checkpoints in ΔPK's anti-tumor activity.

Main Methods:

• Utilized melanoma cell models treated with ΔPK.
• Assessed changes in cytokine secretion (IL-10, TNF-α, GM-CSF, IL-1β) and immune checkpoint expression (MIC-A, CTLA-4).
• Investigated signaling pathways including c-Jun N-terminal kinase/c-Jun, autophagy, Toll-like receptor 2, and pyroptosis.

Main Results:

• ΔPK inhibited immunosuppressive IL-10 secretion via virus replication and c-Jun activation.
• ΔPK upregulated NKG2D ligand MIC-A expression.
• ΔPK promoted inflammatory cytokine secretion and inhibited CTLA-4 expression through TLR2 and pyroptosis pathways.

Conclusions:

• ΔPK-mediated oncolysis effectively reverses the immunosuppressive tumor microenvironment in melanoma.
• The mechanism involves modulating cytokine profiles and immune checkpoint regulators.
• Targeting these pathways enhances the anti-tumor immune response, crucial for oncolytic virotherapy efficacy.